Literature DB >> 6504946

Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect.

E Ernst, M Rose, R Lee.   

Abstract

A study was carried out in 40 patients undergoing minor surgery to investigate the effect of hydroxychloroquine on haemorrheological parameters which might explain its reported anti-thrombotic action. Twenty patients received 600 mg to 1400 mg hydroxychloroquine sulphate in the 48-hour period before operation and the control group of 20 patients received placebo. Blood samples were taken during the 24 hours before and on the day after operation. The results showed that in the hydroxychloroquine-treated group the transoperative increase in fibrinogen was associated with a reduction in plasma viscosity compared with an increase in the control group. Furthermore, the mean value for whole blood viscosity at middle shear rate decreased post-operatively in the drug-treated group whereas it increased in patients who had received placebo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6504946

Source DB:  PubMed          Journal:  Pharmatherapeutica        ISSN: 0308-051X


  6 in total

Review 1.  Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.

Authors:  Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 2.  Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.

Authors:  Claire de Moreuil; Zarrin Alavi; Elisabeth Pasquier
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

3.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.

Authors:  J Calvo-Alén; G McGwin; S Toloza; M Fernández; J M Roseman; H M Bastian; E J Cepeda; E B González; B A Baethge; B J Fessler; L M Vilá; J D Reveille; G S Alarcón
Journal:  Ann Rheum Dis       Date:  2005-11-03       Impact factor: 19.103

4.  Nanoparticles of ZnO/Berberine complex contract COVID-19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity.

Authors:  Doaa A Ghareeb; Samar R Saleh; Mohamed G Seadawy; Mohammed S Nofal; Shaymaa A Abdulmalek; Salma F Hassan; Shaimaa M Khedr; Miral G AbdElwahab; Ahmed A Sobhy; Ali Saber Ali Abdel-Hamid; Abdelrahman Mohamed Yassin; Alshimaa A Abd Elmoneam; Aliaa A Masoud; Mohamed M Y Kaddah; Sally A El-Zahaby; Abdulaziz Mohsen Al-Mahallawi; Alaa M El-Gharbawy; Ahmed Zaki; Inas K Seif; Marwa Y Kenawy; Magdy Amin; Khaled Amer; Maha Adel El Demellawy
Journal:  J Pharm Investig       Date:  2021-09-06

5.  Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study.

Authors:  Elisabeth Pasquier; Luc de Saint-Martin; Gisèle Marhic; Celine Chauleur; Caroline Bohec; Florence Bretelle; Véronique Lejeune-Saada; Jacob Hannigsberg; Geneviève Plu-Bureau; Virginie Cogulet; Philippe Merviel; Dominique Mottier
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

Review 6.  The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?

Authors:  Eugenia Quiros Roldan; Giorgio Biasiotto; Paola Magro; Isabella Zanella
Journal:  Pharmacol Res       Date:  2020-05-13       Impact factor: 7.658

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.